Gitnux/Report 2026

Oral Glp-1 Industry Statistics

The oral GLP-1 industry reached DKK 10.9 billion in Wegovy pill sales during the first nine months of 2026, explore growth, company data, and trends across dosing and competition.
18Statistics
23Sources
5Sections
1Visuals
16mRead
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The oral glp-1 industry at a glance

The oral GLP-1 industry reached DKK 10.9 billion in Wegovy pill sales during the first nine months of 2026, as FDA-approved obesity pills expanded beyond diabetes treatment and attracted new users.

DKK 10.9B[1]
Wegovy pill sales, 9M 2026
DKK 14.7B[1]
Rybelsus sales, 9M 2026
~30%[6]
Oral obesity market share, 2026
23.8%[4]
Oral GLP-1 forecast CAGR, 2026–2034
Market size
One market estimate values the global oral GLP-1 market at $6.2 billion in 2025. Company-reported sales provide a narrower commercial benchmark: Novo Nordisk recorded DKK 10.868 billion in Wegovy pill sales during the first nine months of 2026, alongside DKK 14.738 billion for Ozempic pill/Rybelsus.[4][1]
Forecast & CAGR
Intelevoresearch forecasts the oral GLP-1 market to grow from $6.2 billion in 2025 to $42.5 billion by 2034, representing a 23.8% CAGR from 2026 to 2034. A separate forecast estimates growth from $1.552 billion in 2025 to $3.193 billion in 2032, equal to an 11.7% CAGR, illustrating substantial variation by market definition.[4][5]
Market share & regions
Novo Nordisk reported that Wegovy pill had launched in the United States, United Arab Emirates, United Kingdom and Germany by the end of the third quarter of 2026. Its investor presentation reported approximately 30% share of the total obesity market for oral obesity medicines, based on the 12 weeks ending August 28, 2026.[6]
Segmentation
The industry is segmented by indication, including type 2 diabetes and obesity or weight management, and by molecule type, including peptide-based oral semaglutide and small-molecule agents such as orforglipron. FDA labeling lists Wegovy tablets in 1.5 mg, 4 mg, 9 mg and 25 mg strengths, with a recommended 25 mg maintenance dose for weight reduction and cardiovascular-risk reduction.[10][12]
Key players & concentration
The commercial market is highly concentrated around Novo Nordisk and Eli Lilly. Novo Nordisk reported DKK 10.868 billion in Wegovy pill sales in the first nine months of 2026, while Eli Lilly received U.S. approval for Foundayo, a once-daily small-molecule oral GLP-1, in April 2026.[1][12]
Pricing
Novo Nordisk launched Wegovy pill with a $149 monthly self-pay offer for the starting dose, with the 4 mg dose priced at $149 per month through April 15, 2026, then $199, while the highest doses were listed at $299. Novo Nordisk separately announced a $675 list price for Wegovy tablets 25 mg effective January 1, 2027.[6]
Trends, drivers & challenges
Convenience and market expansion are major drivers: about 80% of Wegovy pill users were GLP-1-obesity-treatment-naive in 2026, and more than 7 million prescriptions had been written year to date in Novo Nordisk’s reported dataset. Challenges include gastrointestinal adverse effects, daily dosing and oral semaglutide administration requirements, including dose escalation and timing restrictions in the FDA label.[6][10]
Consumer behavior & competition
Novo Nordisk reported that approximately 90% of Wegovy pill prescriptions were self-pay, about 70% of users were female, and approximately 80% were new to GLP-1 obesity medicines in 2026. Competition intensified after Eli Lilly launched Foundayo, which can be taken at any time of day without food or water restrictions, unlike oral semaglutide’s labeled administration requirements.[6][12][10]
Regulation
The FDA approved oral Wegovy for chronic weight management and cardiovascular-risk reduction in adults with obesity or overweight and established cardiovascular disease. The FDA label also warns against use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and does not recommend combining it with other GLP-1 receptor agonists.[10][13]
Latest news
The latest company-reported update is Novo Nordisk’s third-quarter 2026 release, which said Wegovy pill sales reached DKK 5.394 billion in the quarter and that the product had launched in the United States, United Arab Emirates, United Kingdom and Germany. Novo Nordisk also reported that weekly new-to-brand prescriptions were approximately 100% above pre-launch levels under the Rybelsus brand.[6]

02 Ranking

Top 10 Companies in the Oral Glp-1 Industry

The leading companies in the oral glp-1 industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Eli Lilly and Company stands out for competing oral small-molecule GLP-1 convenience because it received U.S. approval for Foundayo, a once-daily small-molecule oral GLP-1, in April 2026, while Roche is the pick for oral GLP-1 receptor-agonist development since it is advancing CT-996, an oral small-molecule GLP-1 receptor agonist.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in oral small-molecule GLP-1

    Eli Lilly and Company

    US

    Ranked #1 · 9.9 · Oral small-molecule GLP-1

    Why we picked it: It participates in oral GLP-1 via Orforglipron and reported revenue growth of 44.7% with an operating margin of 40.4%.

  2. #2 overall

    Roche

    CH

    Ranked #2 · 9.1 · Oral small-molecule GLP-1

    Why we picked it: It runs CT-996 in oral small-molecule GLP-1, with 7% revenue growth and R&D at 19.8% of revenue.

  3. Leader in oral semaglutide

    Novo Nordisk

    DK

    Ranked #5 · 8.9 · Oral semaglutide

    Why we picked it: It monetizes oral semaglutide at scale with DKK 14.738 billion for Ozempic pill/Rybelsus over the same period.

Pick 1 is the #1 company overall. Pick 2 is the highest-ranked company in the top 5 that adds a new segment; no further segment places in the top 5, so pick 3 follows rank.

Full ranking

Sort by
Top 10 companies in the oral glp-1 industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Oral small-molecule GLP-1 · US

9.9
2

Roche

Oral small-molecule GLP-1 · CH

9.1
3

AstraZeneca

Oral small-molecule GLP-1 · GB

9.1
4

Jiangsu Hengrui Pharmaceuticals

Oral small-molecule GLP-1 · CN

9.0
5

Novo Nordisk

Oral semaglutide · DK

8.9
6

Merck

Oral GLP-1 receptor agonist development, global · US

8.7
7

Pfizer

Oral GLP-1 receptor agonist development, global · US

8.6
8

MindRank

MDR-001 oral GLP-1 development in China · CN

8.2
9

Ascletis Pharma

ASC30 oral GLP-1 development · CN

7.9
10

Viking Therapeutics

Oral VK2735 GLP-1/GIP development · US

7.8

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 10 companies in the oral glp-1 industry. In Oral Glp-1 Industry Statistics. Gitnux. https://gitnux.org/oral-glp-1-industry-statistics/#top-companies

report visual · Projection

Global Rybelsus (oral semaglutide) net sales

Global Rybelsus (oral semaglutide) net sales grew from 1,873 DKK million in 2020 to 23,301 DKK million in 2024.

1,873 DKK million
Start
+87.81%
CAGR · 4y
23.3K DKK million
Projected
20202024
source-verifiednovonordisk.com2024

04 Statistics

Technology

Technology coverage separates peptide-based oral semaglutide from oral small-molecule GLP-1 programs, including multiple Phase 3 timelines in 2025–2026.

R&D, patents and design rights in the oral glp-1 industry

  • 1 oral GLP-1 receptor agonist, aleniglipron, entered a Phase 3 ACCOMPLISH program in August 2026 for chronic weight management.[1]
  • 1 oral semaglutide product, 25 mg and 50 mg Wegovy tablets, was approved in the United States and listed as a phase-3-or-filed oral GLP-1 asset in Novo Nordisk’s 2025 report.[1]
  • 1 oral GLP-1/GIP receptor agonist candidate, VK2735, completed Phase 2 clinical development in 2025, according to Viking Therapeutics’ annual-report filing.[1]

05 Statistics

Market Intelligence

Market intelligence centers on branded pill sales and widely dispersed forecast definitions, anchored by DKK 10.9B Wegovy pill sales (9M 2026) and DKK 14.7B Rybelsus sales (9M 2026).

Market size, volume and shipments in the oral glp-1 industry

  • DKK 8,833 million was Novo Nordisk’s 2025 U.S. Rybelsus sales, measuring the U.S. branded oral semaglutide segment in value terms.[1]
  • DKK 22,093 million was Novo Nordisk’s 2025 global Rybelsus sales, a branded oral semaglutide proxy for the oral GLP-1 market; the product is an oral tablet.[2]
  • USD 5.58 billion was the estimated 2025 global oral GLP-1 drugs market, covering oral drugs segmented by drug, application, end user and region.[3]

Forecast growth and shipments in the oral glp-1 industry

  • 32.0% is the projected 2025–2034 CAGR for the global oral GLP-1 drugs market, forecast from an estimated USD 5.58 billion base in 2025.[3]
  • 23.8% is the projected 2026–2034 CAGR for the global oral GLP-1 market, with market value forecast to rise from USD 6.2 billion in 2025 to USD 42.5 billion in 2034.[4]
  • 11.7% is the projected CAGR for the global oral GLP-1 drug market from 2025 to 2032, with value forecast to increase from USD 1.552 billion to USD 3.193 billion.[5]

06 Statistics

Production & Operations

Production and operations point to scale constraints and capacity expansion, including a €432 million expansion of an Irish tabletting facility in Athlone.

Installed base and productive capacity in oral glp-1

  • 1 Irish tabletting facility in Athlone is being expanded for current and future oral GLP-1 treatments, with the expansion announced at €432 million.[6]
  • 1 Portuguese site, Hovione FarmaCiencia in Loures, performs spray-drying for oral semaglutide active-substance manufacture, according to the EMA assessment report.[7]
  • 2 U.S. production sites support oral Wegovy: Clayton makes active ingredient and Durham makes and packages tablets, according to Novo Nordisk’s 2025 annual report.[2]

07 Statistics

Pricing & Finance

Pricing and finance shows self-pay centrality, with U.S. self-pay pricing for oral Wegovy ranging from $149 to $299 per month by dose as of January 23, 2026.

Prices and price indices for oral glp-1

  • U.S. self-pay pricing for oral Wegovy (semaglutide tablets) ranged from $149 to $299 per month by dose as of January 23, 2026.[1]
  • $649 per month was the U.S. wholesale acquisition cost for Foundayo (orforglipron), Eli Lilly’s oral GLP-1 obesity medicine, at launch in 2026.[8]
  • Eligible U.S. patients could obtain GLP-1 medicines, including oral treatments, for as little as $149 per month through Walgreens self-pay pricing in 2026.[9]

08 Statistics

Regulation & Risk

Regulation and risk are expressed through administration windows and substitution constraints, including a 30-minute minimum interval for Rybelsus and a 10% maximum strength difference for compounded products.

Regulations and compliance for oral glp-1

  • 4 fluid ounces is the maximum amount of plain water specified for taking Rybelsus oral semaglutide tablets under the FDA-approved U.S. prescribing information, revised December 2024.[10]
  • 10% is the maximum strength difference FDA identifies for compounded semaglutide products to qualify as the same, similar or easily substitutable strength under sections 503A and 503B, stated April 1, 2026.[11]
  • 30 minutes is the minimum interval required between taking Rybelsus oral semaglutide tablets and consuming food, beverages or other oral medicines under the FDA-approved U.S. prescribing information, revised December 2024.[10]

Key questions about the oral glp-1 industry

What is the 2025 size of the global oral GLP-1 market?
The global oral GLP-1 market is estimated at $6.2 billion in 2025. This estimate is a market-definition snapshot rather than a company sales total.
How fast is the oral GLP-1 market expected to grow?
Intelevoresearch forecasts growth from $6.2 billion in 2025 to $42.5 billion by 2034, implying a 23.8% CAGR from 2026 to 2034. A separate forecast projects growth from $1.552 billion in 2025 to $3.193 billion in 2032, an 11.7% CAGR.
Which companies lead the oral glp-1 industry?
Eli Lilly and Company stands out for competing oral small-molecule GLP-1 convenience because it received U.S. approval for Foundayo, a once-daily small-molecule oral GLP-1, in April 2026, while Roche is the pick for oral GLP-1 receptor-agonist development since it is advancing CT-996, an oral small-molecule GLP-1 receptor agonist.
What technology shifts are visible in oral GLP-1?
The market spans peptide-based oral semaglutide and small-molecule agents such as orforglipron. Eli Lilly’s Foundayo can be taken at any time of day without food or water restrictions, contrasting with labeled administration requirements for oral semaglutide.
How concentrated is the oral obesity segment commercially?
The commercial market is highly concentrated around Novo Nordisk and Eli Lilly. Novo Nordisk reported about 30% share of the total obesity market for oral obesity medicines based on the 12 weeks ending August 28, 2026.
What dosing, regulatory, and substitution constraints affect patient use?
For Rybelsus, FDA-approved information specifies a minimum 30-minute interval between taking the tablet and consuming food, beverages, or other oral medicines. The FDA label also warns against use in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Oral Glp-1 Industry Statistics. Gitnux. https://gitnux.org/oral-glp-1-industry-statistics
MLA
Samuel Norberg. "Oral Glp-1 Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/oral-glp-1-industry-statistics.
Chicago
Samuel Norberg. 2026. "Oral Glp-1 Industry Statistics." Gitnux. https://gitnux.org/oral-glp-1-industry-statistics.